Advances in computational structure-based drug design and application in drug discovery

Current Topics in Medicinal Chemistry

Volumn 16, Issue 9, 2016, Pages 901-916

  Wang, Tao ^a,b   Wu, Mian Bin ^a,b   Zhang, Ri Hao ^b   Chen, Zheng Jie ^c   Hua, Chen ^b   Lin, Jian Ping ^a,b   Yang, Li Rong ^a,b  

^a Key Laboratory of Biomass Chemical Engineering of Ministry of Education   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Zhejiang Key Laboratory of Antifungal Drugs   (China)

Author keywords

Antibacterial drugs; Anticancer drugs; De novo design; Inhibitors of GPCRs; Structure based drug design; Virtual screening

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BIOCHEMICAL ANALYSIS; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; EXPERIMENTAL DESIGN; MOLECULAR DYNAMICS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; STRUCTURE BASED DRUG DESIGN; THREE DIMENSIONAL IMAGING; CHEMICAL STRUCTURE; DRUG DEVELOPMENT;

DRUG DESIGN; DRUG DISCOVERY; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 84959548116     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150825142002     Document Type: Article

References (163)

1. Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H. W.; Scheld, W. M.; Bartlett, J. G.; Edwards, J. The epidemic of antibiotic- resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis., 2008, 46 (2), 155-164.
2. Head, M. G.; Fitchett, J. R.; Cooke, M. K.; Wurie, F. B.; Hayward, A. C.; Atun, R. UK investments in global infectious disease research 1997-2010: a case study. Lancet. Infect. Dis., 2013, 13 (1), 55-64.
3. Team, W. H. O. E. R. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N. Engl. J. Med., 2014, 371 (16), 1481-1495.
4. Levy, J. A.; Autran, B.; Coutinho, R. A.; Phair, J. P. 25 Years of AIDS: recording progress and future challenges. AIDS, 2012, 26 (10), 1187-1189.
5. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics.CA-Cancer J. Clin., 2011, 61 (2), 69-90.
6. Anonymous. Less talk, more action.Nat. Rev. Microbiol., 2013, 11 (5), 295-295.
7. Alvan, G.; Edlund, C.; Heddini, A. The global need for effective antibiotics—a summary of plenary presentations. Drug Resist. Update., 2011, 14 (2), 70-76.
8. Piddock, L. J. The crisis of no new antibiotics—what is the way forward? Lancet. Infect. Dis., 2012, 12 (3), 249-253.
9. White, A. R.; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J. Antimicrob. Chemother., 2011, 66(9), 1948-1953.
10. Li, J. W.; Vederas, J. C. Drug discovery and natural products: end of an era or an endless frontier? Science 2009, 325(5937), 161-165.
11. Drews, J. Drug discovery: a historical perspective. Science 2000, 287(5460), 1960-1964.
12. Swinney, D.C.; Anthony, J. How were new medicines discovered? Nat.Rev. Drug Discov., 2011, 10(7), 507-519.
13. Newman, D. J.; Cragg, G. M.; Snader, K. M. The influence of natural products upon drug discovery. Nat. Prod. Rep., 2000, 17(3), 215-234.
14. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432(7019), 862-865.
15. Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S. H. Structurebased virtual screening for drug discovery: a problem-centric review. AAPS J., 2012, 14(1), 133-141.
16. Wang, T.; Wu, M.B.; Chen, Z.J.; Chen, H.; Lin, J.P.; Yang, L.R. Fragment-Based Drug Discovery and Molecular Docking in Drug Design. Curr. Pharm. Biotechnol., 2015, 16(1), 11-25.
17. Schreiber, S. L. Organic synthesis toward small-molecule probes and drugs. Proc. Natl. Acad. Sci. U S A., 2011, 108(17), 6699-6702.
18. Nadin, A.; Hattotuwagama, C.; Churcher, I. Lead- Oriented Synthesis: A New Opportunity for Synthetic Chemistry. Angew. Chem. Int. Ed. Engl., 2012, 51(5), 1114-1122.
19. Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E. W. Computational methods in drug discovery. Pharmacol.Rev., 2014, 66(1), 334-395.
20. Lionta, E.; Spyrou, G.; Vassilatis, D. K.; Cournia, Z. Structurebased virtual screening for drug discovery: Principles, applications and recent advances. Curr. Top. Med. Chem., 2014, 14(16), 1923.
21. Agrawal, P. Structure-based drug design. J. Pharmacovigil., 2013, 01(04)doi:10.4172/2329-6887.1000e1 11.
22. Simmons, K. J.; Chopra, I.; Fishwick, C. W. Structure-based discovery of antibacterial drugs. Nat. Rev. Microbio., 2010, 8 (7), 501-510.
23. Jorgensen, W. L. Drug discovery: Pulled from a protein's embrace. Nature 2010, 466(7302), 42-43.
24. Kubinyi, H. Combinatorial and computational approaches in structure- based drug design. Curr. Opin. Drug Discov. Dev, 1998, 1, 16-27.
25. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug. Discov., 2009, 8(3), 203-212.
26. Goodnow Jr, R. A., Hit and lead identification: Integrated technology- based approaches. Drug Discov. Today: Technol., 2007, 3, (4), 367-375.
27. Keseru, G. M.; Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug. Discov., 2009, 8(3), 203-212.
28. Nagaraju, M.; McGowan, L. C.; Hamelberg, D. Cyclophilin A inhibition: targeting transition-state-bound enzyme conformations for structure-based drug design. J. Chem. Inf. Model., 2013, 53(2), 403-410.
29. Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R. N.; Burke, J. P.; Garcia- Barrantes, P. M.; Camper, D.; Chauder, B. A.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J. Med. Chem., 2013, 56(1), 15-30.
30. Cheng, H.; Li, C.; Bailey, S.; Baxi, S. M.; Goulet, L.; Guo, L.; Hoffman, J.; Jiang, Y.; Johnson, T. O.; Johnson, T. W.; Knighton, D. R.; Li, J.; Liu, K. K.; Liu, Z.; Marx, M. A.; Walls, M.; Wells, P. A.; Yin, M. J.; Zhu, J.; Zientek, M. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through sructure-based drug design. ACS Med. Chem. Lett., 2013, 4(1), 91-97.
31. Fells, J. I.; Tsukahara, R.; Liu, J.; Tigyi, G.; Parrill, A. L., Structure- based drug design identifies novel LPA3 antagonists. Bioorg. Med. Chem., 2009, 17(21), 7457-7464.
32. Lam, P.; Jadhav, P.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science, 1994, 263(5145), 380-384.
33. Aparoy, P.; Reddy, K. K.; Reddanna, P. Structure and ligand based drug design strategies in the development of novel 5-LOX inhibitors. Curr. Med. Chem., 2012, 19(22), 3763-3778.
34. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol. Rev., 2011, 63(4), 901-937.
35. Bellenie, B. R.; Barton, N. P.; Emmons, A. J.; Heer, J. P.; Salvagno, C. Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design. Bioorg. Med. Chem. Lett., 2009, 19(3), 990-994.
36. Al-Asri, J.; Wolber, G. Discovery of novel α-amylase inhibitors using structure-based drug design. J. Cheminformatics, 2014, 6(Suppl 1), P50.
37. Flipo, M.; Desroses, M.; Lecat-Guillet, N.; Villemagne, B.; Blondiaux, N.; Leroux, F.; Piveteau, C.; Mathys, V.; Flament, M. P.; Siepmann, J.; Villeret, V.; Wohlkonig, A.; Wintjens, R.; Soror, S. H.; Christophe, T.; Jeon, H. K.; Locht, C.; Brodin, P.; Deprez, B.; Baulard, A. R.; Willand, N. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1, 2, 4-oxadiazole EthR inhibitors. J. Med. Chem., 2012, 55(1), 68-83.
38. Grant, M. A. Protein structure prediction in structure-based ligand design and virtual screening. Comb. Chem. High Throughput. Screen., 2009, 12(10), 940-960.
39. Durand, P.; Golinelli-Pimpaneau, B.; Mouilleron, S.; Badet, B.; Badet-Denisot, M. A. Highlights of glucosamine-6-P synthase catalysis. Arch. Biochem. Biophys., 2008, 474(2), 302-317.
40. Gamble, T. R.; Vajdos, F. F.; Yoo, S.; Worthylake, D. K.; Houseweart, M.; Sundquist, W. I.; Hill, C. P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV- 1 capsid. Cell, 1996, 87(7), 1285-1294.
41. Luban, J.; Bossolt, K. L.; Franke, E. K.; Kalpana, G. V.; Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell, 1993, 73(6), 1067-1078.
42. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A. Rational design of peptide-based HIV proteinase inhibitors. Science, 1990, 248(4953), 358-361.
43. Backbro, K.; Lowgren, S.; Osterlund, K.; Atepo, J.; Unge, T.; Hulten, J.; Bonham, N. M.; Schaal, W.; Karlen, A.; Hallberg, A. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J. Med. Chem., 1997, 40(6), 898-902.
44. Yang, J. S.; Chen, W. W.; Skolnick, J.; Shakhnovich, E. I. All-atom ab initio folding of a diverse set of proteins. Structure, 2007, 15(1), 53-63.
45. Dolan, M. A.; Noah, J. W.; Hurt, D. Comparison of common homology modeling algorithms: application of user-defined alignments. Methods Mol. Biol., 2012, 857, 399-414.
46. Schwede, T. Homology modeling of protein structures. Encyclopedia of Biophysics, Springer, 2013, pp 992-998.
47. Eswar, N.; Webb, B.; Marti-Renom, M. A.; Madhusudhan, M.; Eramian, D.; Shen, M. y.; Pieper, U.; Sali, A. Comparative protein structure modeling using Modeller. Curr. protoc. bioinformatics, 2006, 5. 1-5.6. 30.
48. Bordoli, L.; Schwede, T. Automated protein structure modeling with SWISS-MODEL workspace and the protein model portal. Methods Mol. Biol., 2012, 857, 107-136.
49. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISSMODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22(2), 195-201.
50. Bordoli, L.; Kiefer, F.; Arnold, K.; Benkert, P.; Battey, J.; Schwede, T. Protein structure homology modeling using SWISSMODEL workspace. Nat.Protoc., 2008, 4(1), 1-13.
51. Tramontano, A.; Leplae, R.; Morea, V. Analysis and assessment of comparative modeling predictions in CASP4. Proteins, 2001, 45(S5), 22-38.
52. Perez-Nueno, V. I.; Pettersson, S.; Ritchie, D. W.; Borrell, J. I.; Teixido, J. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J. Chem. Inf. Model., 2009, 49(4), 810-823.
53. Kirchmair, J.; Distinto, S.; Schuster, D.; Spitzer, G.; Langer, T.; Wolber, G. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr. med. chem., 2008, 15(20), 2040-2053.
54. Wiederstein, M.; Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res., 2007, 35, 407-410.
55. Eramian, D.; Eswar, N.; Shen, M. Y.; Sali, A. How well can the accuracy of comparative protein structure models be predicted? Protein Sci., 2008, 17(11), 1881-1893.
56. Wang, Z.; Tegge, A. N.; Cheng, J. Evaluating the absolute quality of a single protein model using structural features and support vector machines. Proteins, 2009, 75(3), 638-647.
57. Benkert, P.; Biasini, M.; Schwede, T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics, 2011, 27(3), 343-350.
58. Giri, R.; Morrone, A.; Toto, A.; Brunori, M.; Gianni, S. Structure of the transition state for the binding of c-Myb and KIX highlights an unexpected order for a disordered system. Proc. Natl. Acad. Sci. USA., 2013, 110(37), 14942-14947.
59. Wright, P. E.; Dyson, H. J. Intrinsically disordered proteins in cellular signalling and regulation. Nat. Rev. Mol. Cell Biol., 2015, 16(1), 18-29.
60. Uversky, V. N.; Oldfield, C. J.; Dunker, A. K. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 2008, 37, 215-246.
61. Metallo, S. J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol., 2010, 14(4), 481-488.
62. Nisius, B.; Sha, F.; Gohlke, H. Structure-based computational analysis of protein binding sites for function and druggability prediction. J.biotechnol., 2012, 159(3), 123-134.
63. Kellenberger, E.; Schalon, C.; Rognan, D. How to measure the similarity between protein ligand-binding sites? Curr. Compu.-Aid Drug 2008, 4(3), 1-12.
64. Jambon, M.; Imberty, A.; Deleage, G.; Geourjon, C. A new bioinformatic approach to detect common 3D sites in protein structures. Proteins, 2003, 52(2), 137-145.
65. Stark, A.; Russell, R. B. Annotation in three dimensions. PINTS: Patterns in Non-homologous Tertiary Structures. Nucleic Acids Res., 2003, 31(13), 3341-3344.
66. Schalon, C.; Surgand, J. S.; Kellenberger, E.; Rognan, D. A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins, 2008, 71(4), 1755-1778.
67. Ripphausen, P.; Nisius, B.; Peltason, L.; Bajorath, J. Quo vadis, virtual screening? A comprehensive survey of prospective applications. J. Med. Chem., 2010, 53(24), 8461-8467.
68. Clark, D. E. What has virtual screening ever done for drug discovery? Expert Opin. Drug Discov., 2008, 3(8):841-851.
69. Cummings, M. D.; Maxwell, A. C.; DesJarlais, R. L. Processing of small molecule databases for automated docking. Med. Chem., 2007, 3(1), 107-113.
70. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J.Med.Chem., 2010, 53(7), 2719-2740.
71. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Privileged scaffolds for library design and drug discovery. Curr.Opin.Chem.Biol., 2010, 14(3), 347-361.
72. Wang, T.; Wu, M.; Chen, Z.; Lin, J.; Yang, L. Fragment-Based Drug Discovery and Molecular Docking in Drug Design. Curr. Pharm. Biotechnol., 2015, 16(1):11-25.
73. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J.Comput.Chem., 2010, 31(2), 455-461.
74. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J.Mol.Biol., 1996, 261(3), 470-489.
75. Teague, S. J. Implications of protein flexibility for drug discovery. Nat.Rev. Drug Discov., 2003, 2(7), 527-541.
76. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J.Comput.Chem., 2009, 30(16), 2785-2791.
77. Fuhrmann, J.; Rurainski, A.; Lenhof, H. P.; Neumann, D. A new Lamarckian genetic algorithm for flexible ligand-receptor docking. J. Comput. Chem., 2010, 31(9), 1911-1918.
78. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE). J.Comput-Aid Mol.Design 2008, 22(5), 311-325.
79. Pujadas, G.; Vaque, M.; Ardevol, A.; Blade, C.; Salvado, M.; Blay, M.; Fernandez-Larrea, J.; Arola, L. Protein-ligand docking: A review of recent advances and future perspectives. Curr. Pharm. Anal., 2008, 4(1), 1-19.
80. Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: a powerful approach for structure-based drug discovery. Curr.Comput-Aid Drug Des., 2011, 7(2), 146.
81. Yuriev, E.; Agostino, M.; Ramsland, P. A. Challenges and advances in computational docking: 2009 in review. J.Mol. Recognit., 2011, 24(2), 149-164.
82. Fitzpatrick, L. R.; Deml, L.; Hofmann, C.; Small, J. S.; Groeppel, M.; Hamm, S.; Lemstra, S.; Leban, J.; Ammendola, A. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm. Bowel. Dis., 2010, 16(10), 1763-1777.
83. Coumar, M. S.; Leou, J-S.; Shukla, P.; Wu, J.S.; Dixit, A. K.; Lin, W.H.; Chang, C-Y.; Lien, T.W.; Tan, U.K.; Chen, C.H., Structurebased drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. J. Med. Chem., 2009, 52(4), 1050-1062.
84. Odell, L. R.; Howan, D.; Gordon, C. P.; Robertson, M. J.; Chau, N.; Mariana, A.; Whiting, A. E.; Abagyan, R.; Daniel, J. A.; Gorgani, N. N. The pthaladyns: GTP competitive inhibitors of dynamin I and II GTPase derived from virtual screening. J. Med. Chem., 2010, 53(14), 5267-5280.
85. Ballester, P. J.; Mangold, M.; Howard, N. I.; Robinson, R. L. M.; Abell, C.; Blumberger, J.; Mitchell, J. B. Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification. J. R. Soc. Interface., 2012, 9(77), 3196-3207.
86. Distinto, S.; Esposito, F.; Kirchmair, J.; Cardia, M. C.; Gaspari, M.; Maccioni, E.; Alcaro, S.; Markt, P.; Wolber, G.; Zinzula, L. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint-and pharmacophore-based virtual screening approach. Euro.J.Med.Chem., 2012, 50, 216-229.
87. Alberici, L.; Roth, L.; Sugahara, K. N.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Bordignon, C.; Traversari, C.; Rizzardi, G.-P.; Ruoslahti, E. De novo design of a tumor-penetrating peptide. Cancer Res., 2013, 73(2), 804-812.
88. Rodrigues, T.; Roudnicky, F.; Koch, C. P.; Kudoh, T.; Reker, D.; Detmar, M.; Schneider, G. De novo design and optimization of Aurora A kinase inhibitors. Chem. Sci., 2013, 4(3), 1229-1233.
89. Kalyaanamoorthy, S.; Chen, Y.P. P. Structure-based drug design to augment hit discovery. Drug Discov.Today, 2011, 16(17), 831-839.
90. Murray, C. W.; Blundell, T. L. Structural biology in fragmentbased drug design. Curr.Opin.Struc.Biol., 2010, 20(4), 497-507.
91. Schneider, G.; Fechner, U., Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov., 2005, 4(8), 649-663.
92. Bohm, H. J., The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput-Aid Mol.Des., 1992, 6(1), 61-78.
93. Law, J. M.; Fung, D. Y.; Zsoldos, Z.; Simon, A.; Szabo, Z.; Csizmadia, I. G.; Johnson, A. P. Validation of the SPROUT de novo design program. J.Mol. Struc. THEOCHEM, 2003, 666, 651-657.
94. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Boehm, H.-J.; Dean, P. M. A validation study on the practical use of automated de novo design. J. Comput-Aid Mol.Des., 2002, 16(7), 459-478.
95. Fechner, U.; Schneider, G. Flux (1): a virtual synthesis scheme for fragment-based de novo design. J. Chem. Inf. Model., 2006, 46(2), 699-707.
96. Dey, F.; Caflisch, A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J. Chem. Inf. Model., 2008, 48(3), 679-690.
97. Loving, K.; Alberts, I.; Sherman, W. Computational approaches for fragment-based and de novo design. Curr. Top. Med. Chem., 2010, 10(1), 14-32.
98. Jorgensen, W. L. The many roles of computation in drug discovery. Science 2004, 303(5665), 1813-1818.
99. Lauri, G.; Bartlett, P. A. CAVEAT: a program to facilitate the design of organic molecules. J.Comput-Aid Mol.Des., 1994, 8(1), 51-66.
100. Gillet, V. J.; Newell, W.; Mata, P.; Myatt, G.; Sike, S.; Zsoldos, Z.; Johnson, A. P. SPROUT: recent developments in the de novo design of molecules. J. Chem. Inf. Comput. Sci., 1994, 34(1), 207-217.
101. Bohm, H.J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J.Comput-Aid Mol.Des., 1992, 6(1), 61-78.
102. Boehm, H.J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier- Keller, N. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem., 2000, 43(14), 2664-2674.
103. McCamm0n, J. A. Dynamics of folded proteins. Nature 1977, 267, 585-590.
104. Hansson, T.; Oostenbrink, C.; van Gunsteren, W. Molecular dynamics simulations. Curr.Opin.Struc.Biol., 2002, 12(2), 190-196.
105. Tubert-Brohman, I.; Acevedo, O.; Jorgensen, W. L. Elucidation of hydrolysis mechanisms for fatty acid amide hydrolase and its Lys142Ala variant via QM/MM simulations. J. Am. Chem. Soc.2006, 128(51), 16904-16913.
106. Raval, A.; Piana, S.; Eastwood, M. P.; Dror, R. O.; Shaw, D. E. Refinement of protein structure homology models via long, all-atom molecular dynamics simulations. Proteins, 2012, 80(8), 2071-2079.
107. Borkar, A.; Ghosh, I.; Bhattacharyya, D. Structure and dynamics of double helical DNA in torsion angle hyperspace: A molecular mechanics approach. J. Biomol. Struct. Dyn., 2010, 27(5), 695-712.
108. Eklund, R.; Widmalm, G. Molecular dynamics simulations of an oligosaccharide using a force field modified for carbohydrates. Carbohydr. Res., 2003, 338(5), 393-398.
109. Cournia, Z.; Allen, T. W.; Andricioaei, I.; Antonny, B.; Baum, D.; Brannigan, G.; Buchete, N.-V.; Deckman, J. T.; Delemotte, L.; del Val, C. Membrane Protein Structure, Function, and Dynamics: a Perspective from Experiments and Theory. J.Membr.Biol., 2015, 1-30.
110. Trick, J. L.; Aryal, P.; Tucker, S. J.; Sansom, M. Molecular simulation studies of hydrophobic gating in nanopores and ion channels. Biochem. Soc.Trans., 2015, 43(2), 146-150.
111. Zhu, J.; Fan, H.; Periole, X.; Honig, B.; Mark, A. E. Refining homology models by combining replica-exchange molecular dynamics and statistical potentials. Proteins, 2008, 72(4), 1171-1188.
112. Chen, J.; Brooks, C. L. Can molecular dynamics simulations provide high-resolution refinement of protein structure? Proteins, 2007, 67(4), 922-930.
113. Nair, P. C.; Malde, A. K.; Mark, A. E. Using Theory to Reconcile Experiment: The Structural and Thermodynamic Basis of Ligand Recognition by Phenylethanolamine N-Methyltransferase (PNMT).J. Chem. Theory Comput., 2011, 7(5), 1458-1468.
114. Nair, P. C.; Malde, A. K.; Drinkwater, N.; Mark, A. E. Missing fragments: Detecting cooperative binding in fragment-based drug design. ACS Med. Chem. Lett., 2012, 3(4), 322-326.
115. Grant, B. J.; Lukman, S.; Hocker, H. J.; Sayyah, J.; Brown, J. H.; McCammon, J. A.; Gorfe, A. A. Novel allosteric sites on Ras for lead generation. PLoS One 2011, 6(10), e25711.
116. Durrant, J. D.; Keranen, H.; Wilson, B. A.; McCammon, J. A. Computational identification of uncharacterized cruzain binding sites. PLoS Negl. Trop. Dis., 2010, 4(5), e676.
117. Ivetac, A.; Andrew McCammon, J. Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem.Biol.Drug Des., 2010, 76(3), 201-217.
118. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc., 1995, 117(19), 5179-5197.
119. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. chem., 1983, 4(2), 187-217.
120. Scott, W. R.; Hunenberger, P. H.; Tironi, I. G.; Mark, A. E.; Billeter, S. R.; Fennen, J.; Torda, A. E.; Huber, T.; Kruger, P.; van Gunsteren, W. F. The GROMOS biomolecular simulation program package. J. Phys. Chem. A, 1999, 103(19), 3596-3607.
121. Nelson, M. T.; Humphrey, W.; Gursoy, A.; Dalke, A.; Kale, L. V.; Skeel, R. D.; Schulten, K. NAMD: a parallel, object-oriented molecular dynamics program. Int. J. High Perform. C., 1996, 10(4), 251-268.
122. Ma, B.; Shatsky, M.; Wolfson, H. J.; Nussinov, R. Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations. Protein Sci., 2002, 11(2), 184-197.
123. Buch, I.; Giorgino, T.; De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc. Natl. Acad. Sci. USA., 2011, 108(25), 10184-10189.
124. Wang, J.; Ma, C.; Fiorin, G.; Carnevale, V.; Wang, T.; Hu, F.; Lamb, R. A.; Pinto, L. H.; Hong, M.; Klein, M. L. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J. Am. Chem. Soc., 2011, 133(32), 12834-12841.
125. Zhang, S. Computer-aided drug discovery and development. In Drug Design and Discovery, Springer: 2011; pp 23-38.
126. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110(18), 5959-5967.
127. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37(24), 4130-4146.
128. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J.Chem.Inf. model., 2005, 45(1), 160-169.
129. Chen, J.; Lai, L. Pocket v. 2: further developments on receptorbased pharmacophore modeling. J.Chem.Inf. model., 2006, 46(6), 2684-2691.
130. Ortuso, F.; Langer, T.; Alcaro, S. GBPM: GRID-based pharmacophore model: concept and application studies to protein–protein recognition. Bioinformatics, 2006, 22(12), 1449-1455.
131. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov., 2011, 10(3), 197-208.
132. Butina, D.; Segall, M. D.; Frankcombe, K. Predicting ADME properties in silico: methods and models. Drug Discov. Today, 2002, 7(11), 83-88.
133. Michel, J.; Foloppe, N.; Essex, J. W. Rigorous Free Energy Calculations in Structure-Based Drug Design. Mol. Inf., 2010, 29(9), 570-578.
134. Wlodawer, A.; Vondrasek, J. INHIBITORS OF HIV-1 PROTEASE: amajor success of structure-assisted drug design 1. Annu. Rev. Biophys. Biomol. Struct., 1998, 27(1), 249-284.
135. Herrlinger, K.; Diculescu, M.; Fellermann, K.; Hartmann, H.; Howaldt, S.; Nikolov, R.; Petrov, A.; Reindl, W.; Otte, J.; Stoynov, S. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J. Crohns Colitis, 2013, 7(8), 636-643.
136. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E. Identification of N-(4-Piperidinyl)-4-(2, 6- dichlorobenzoylamino)-1 H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†. J. Med. Chem., 2008, 51(16), 4986-4999.
137. Cui, J. J.; Tran-Dube, M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem., 2011, 54(18), 6342-6363.
138. Fells, J. I.; Tsukahara, R.; Liu, J.; Tigyi, G.; Parrill, A. L., Structure- based drug design identifies novel LPA 3 antagonists. Biorg. Med. Chem., 2009, 17(21), 7457-7464.
139. Rosenbaum, D. M.; Rasmussen, S. G.; Kobilka, B. K. The structure and function of G-protein-coupled receptors. Nature, 2009, 459(7245), 356-363.
140. Christopher, J. A.; Brown, J.; Dore, A. S.; Errey, J. C.; Koglin, M.; Marshall, F. H.; Myszka, D. G.; Rich, R. L.; Tate, C. G.; Tehan, B. Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structurebased drug design. J. Med. Chem., 2013, 56(9), 3446-3455.
141. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B. K.; Shoichet, B. K. Structure-based discovery of β2-adrenergic receptor ligands. Proc. Natl. Acad. Sci.USA., 2009, 106(16), 6843-6848.
142. Mysinger, M. M.; Weiss, D. R.; Ziarek, J. J.; Gravel, S.; Doak, A. K.; Karpiak, J.; Heveker, N.; Shoichet, B. K.; Volkman, B. F. Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4. Proc. Natl. Acad. Sci.USA., 2012, 109(14), 5517-5522.
143. Lewis, K., Platforms for antibiotic discovery. Nat. Rev. Drug Discov., 2013, 12(5), 371-387.
144. McPhillie, M. J.; Trowbridge, R.; Mariner, K. R.; O’Neill, A. J.; Johnson, A. P.; Chopra, I.; Fishwick, C. W. Structure-based ligand design of novel bacterial RNA polymerase inhibitors. ACS Med. Chem. Lett., 2011, 2(10), 729-734.
145. Li, X.; Hilgers, M.; Cunningham, M.; Chen, Z.; Trzoss, M.; Zhang, J.; Kohnen, L.; Lam, T.; Creighton, C.; Gc, K. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2, 4- diaminoquinazolines. Bioorg. Med. Chem. Lett., 2011, 21(18), 5171-5176.
146. Lam, T.; Hilgers, M. T.; Cunningham, M. L.; Kwan, B. P.; Nelson, K. J.; Brown-Driver, V.; Ong, V.; Trzoss, M.; Hough, G.; Shaw, K. J. Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2, 4-diaminoquinazolines. J. Med. Chem., 2014, 57(3), 651-668.
147. Gschwind, A.; Fischer, O. M.; Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 361-370.
148. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy.N. Engl. J. Med., 2005, 353(2), 172-187.
149. Micco, M.; Collie, G. W.; Dale, A. G.; Ohnmacht, S. A.; Pazitna, I.; Gunaratnam, M.; Reszka, A. P.; Neidle, S. Structure-based design and evaluation of naphthalene diimide G-quadruplex ligands as telomere targeting agents in pancreatic cancer cells. J. Med. Chem., 2013, 56(7), 2959-2974.
150. Tsukada, T.; Takahashi, M.; Takemoto, T.; Kanno, O.; Yamane, T.; Kawamura, S.; Nishi, T. Structure-based drug design of tricyclic 8H-indeno[1, 2-d][1, 3]thiazoles as potent FBPase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(3), 1004-1007.
151. de Bruin, G.; Huber, E. M.; Xin, B.-T.; van Rooden, E. J.; Al- Ayed, K.; Kim, K.-B.; Kisselev, A. F.; Driessen, C.; van der Stelt, M.; van der Marel, G. A. Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes. J. Med. Chem., 2014, 57(14), 6197-6209.
152. Claffey, M. M.; Helal, C. J.; Verhoest, P. R.; Kang, Z.; Fors, K. S.; Jung, S.; Zhong, J.; Bundesmann, M. W.; Hou, X.; Lui, S. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J. Med. Chem., 2012, 55(21), 9055-9068.
153. Brodney, M. A.; Barreiro, G.; Ogilvie, K.; Hajos-Korcsok, E.; Murray, J.; Vajdos, F.; Ambroise, C.; Christoffersen, C.; Fisher, K.; Lanyon, L. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer’s disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors. J. Med. Chem., 2012, 55(21), 9224-9239.
154. Cumming, J. N.; Smith, E. M.; Wang, L.; Misiaszek, J.; Durkin, J.; Pan, J.; Iserloh, U.; Wu, Y.; Zhu, Z.; Strickland, C.; Voigt, J.; Chen, X.; Kennedy, M. E.; Kuvelkar, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Czarniecki, M. F.; Greenlee, W. J.; McKittrick, B. A.; Parker, E. M.; Stamford, A. W. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg. Med. Chem. Lett., 2012, 22(7), 2444-2449.
155. Barsanti, P. A.; Pan, Y.; Lu, Y.; Jain, R.; Cox, M.; Aversa, R. J.; Dillon, M. P.; Elling, R.; Hu, C.; Jin, X., Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors. ACS Med. Chem. Lett., 2014, 6(1):42-46.
156. Flipo, M.; Desroses, M.; Lecat-Guillet, N.; Villemagne, B.; Blondiaux, N.; Leroux, F.; Piveteau, C.; Mathys, V.; Flament, M.- P.; Siepmann, J. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1, 2, 4-oxadiazole EthR inhibitors. J. Med. Chem., 2011, 55(1), 68-83.
157. Ernst, J. T.; Neubert, T.; Liu, M.; Sperry, S.; Zuccola, H.; Turnbull, A.; Fleck, B.; Kargo, W.; Woody, L.; Chiang, P. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as huntington’s disease. J. Med. Chem., 2014, 57(8), 3382-3400.
158. Dounay, A. B.; Anderson, M.; Bechle, B. M.; Evrard, E.; Gan, X.; Kim, J.-Y.; McAllister, L. A.; Pandit, J.; Rong, S.; Salafia, M. A. PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency. Bioorg. Med. Chem. Lett., 2013, 23(7), 1961-1966.
159. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J. Med. Chem., 2008, 51(19), 6138-6149.
160. Congreve, M.; Andrews, S. P.; Dore, A. S.; Hollenstein, K.; Hurrell, E.; Langmead, C. J.; Mason, J. S.; Ng, I. W.; Tehan, B.; Zhukov, A. Discovery of 1, 2, 4-triazine derivatives as adenosine A2A antagonists using structure based drug design. J. Med. Chem., 2012, 55(5), 1898-1903.
161. Agarwal, A. K.; Fishwick, C. W.Structure-based design of antiinfectives. Ann. NY Acad. Sci., 2010, 1213, 20-45.
162. Czaplewski, L. G.; Collins, I.; Boyd, E. A.; Brown, D.; East, S. P.; Gardiner, M.; Fletcher, R.; Haydon, D. J.; Henstock, V.; Ingram, P. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg. Med. Chem. Lett., 2009, 19(2), 524-527.
163. Hesterkamp, T.; Whittaker, M., Fragment-based activity space: smaller is better. Curr.Opin.Chem. Biol., 2008, 12(3), 260-268.